This webinar is aimed at Pharma and Biotech professionals who work on rare disease drug development and aim to bring them to market. This includes Clinical development portfolio managers, market access, medical affairs and RWE specialists. ​

​We will be exploring what integrated evidence strategy is, and the practicalities and challenges of generating evidence for rare disease programs.​

We will also be hearing from patient advocacy group representative how they work collaboratively with pharma to make sure their voice is heard and outcomes that matter are included in the evidence plan. ​

​In most healthcare systems worldwide, specialised care is readily available for common medical issues. Unlike common ailments, rare diseases lack specialised care. Real-world studies provide an opportunity to develop comprehensive knowledge, which can aid in identifying variables that impact rare disease outcomes.  ​

​This webinar is intended for pharma, biotech and patient advocacy groups who are interested in advancing their knowledge around the use of real-world studies for rare diseases. It will explore the following:  ​

​Evidence generation framework for rare disease programs  ​

Case studies  ​

Q&A ​